Q

Qualigen Therapeutics
D

QLGN

3.43000
USD
-0.27
(-7.30%)
مغلق
حجم التداول
20
الربح لكل سهم
-6
العائد الربحي
-
P/E
0
حجم السوق
2,525,958
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ARCT
    0.846
    (5.00%)
    17.770 USD
    C
    CRIS
    -0.03400
    (-1.09%)
    3.07600 USD
    M
    MGNX
    -0.13000
    (-4.50%)
    2.76000 USD
    REGN
    REGN
    4.37
    (0.63%)
    700.66 USD
    T
    TGTX
    -0.040
    (-0.13%)
    30.900 USD
    V
    VYGR
    -0.04000
    (-0.94%)
    4.22500 USD
    المزيد
الأخبار
المقالات

العنوان: Qualigen Therapeutics Inc

القطاع: Healthcare
الصناعة: Biotechnology
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.